Generics, authorised low‑cost versions and regulatory action are reshaping South Africa’s GLP‑1 weight‑loss drug market as patients seek cheaper, safer access.
Semaglutide and tirzepatide products are under scrutiny after South Africa’s health regulators warned against the use, prescription and dispensing of recalled iDEXIS medicines. The South African...